3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
FTC v. Actavis
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies -
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: Supreme Court Decision on FTC v. Actavis paves the way for development of cheaper drugs Supreme Court Decision on FTC v. Actavis paves the way for development of cheaper drugs
By Arthur Caplan Zachary D Caplan JD, attorney at law firm in Philadelphia that filed amicus brief on behalf of drug wholesalers and pharmacies in FTC v. Actavis Arthur Caplan PhD, Division of Medical Ethics, NYU Langone Medical Center Amidst all the news about various Supreme Court decisions there is one that ought not be overlooked…